Molecule Structure

Scientific Name

Afatinib

Description of the Drug

Afatinib is an antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08916

Brand Name(s)

Gilotrif, Giotrif

Company Owner(s)

Boehringer Ingelheim

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Epidermal growth factor receptor erbB1 SINGLE PROTEIN INHIBITOR CHEMBL203
Receptor protein-tyrosine kinase erbB-2 SINGLE PROTEIN INHIBITOR CHEMBL1824
Receptor protein-tyrosine kinase erbB-4 SINGLE PROTEIN INHIBITOR CHEMBL3009

Unichem Links

SureChEMBL SCHEMBL185621
PharmGKB PA165981154
DrugBank DB08916
PubChem: Thomson Pharma 15180141
PubChem 10184653
LINCS LSM-43226
Nikkaji J3.363.130H J2.685.397D
PDBe 0WM
BindingDB 50322823
EPA CompTox Dashboard DTXSID20893451
DrugCentral 4318
Brenda 213442
ChemicalBook CB12470923 CB62507657
Guide to Pharmacology 5667
rxnorm AFATINIB GILOTRIF AFATINIB DIMALEATE
PubChem: Drugs of the Future 57304398
ChEBI 61390
ZINC ZINC000003976838